Latest news with #Renovaro
Associated Press
30-06-2025
- Business
- Associated Press
Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs
LOS ANGELES, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Renovaro Inc.'s (NASDAQ:RENB) wholly owned subsidiary BioSymetrics has unveiled a proprietary AI-based zebrafish screening platform designed to rapidly identify medical countermeasures for neurotoxic chemical agents, including weaponized substances like Sarin. The platform has been integrated into Renovaro's Defense Countermeasures Program, marking a strategic entry into the dual-use biotechnology and biodefense sector. Renovaro's platform is anchored by advanced data preprocessing coupled with in vivo toxicity testing, creating a robust, end-to-end discovery pipeline bolstered by their recently announced patent, 'Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions'. This IP milestone expands the company's foundational portfolio, further protecting its machine learning infrastructure for multi-modal biomedical data integration and predictive analytics-core to its scalable drug discovery and diagnostics business. 'This is a defining moment for Renovaro as we extend the value of our AI platform from traditional life sciences into national security,' said David Weinstein, CEO of Renovaro. 'With a growing patent estate and entry into the defense market, we are unlocking new revenue channels and expanding the commercial potential of our core technologies.' Value Drivers: The AI-based platform which uses an inexpensive zebrafish-based model for validation of neurotoxicity predictions, delivers rapid, automated screening of over 1,000 compounds per week, significantly outpacing traditional animal models. It captures behavioural, cardiovascular, and muscular responses to neuroactive chemicals, enabling ML-driven compound triage and mechanism of action prediction. This capability is vital for both commercial CNS drug discovery and defense applications involving neurotoxic exposure. 'Investors increasingly seek companies with platforms that are both scientifically robust and commercially scalable,' said Weinstein. 'Our ability to serve large markets in biopharma and national security - each with deep funding pools and urgent unmet needs - creates a unique, de-risked growth trajectory.' About Renovaro Inc. Renovaro Inc. (NASDAQ: RENB) is building category-defining AI-driven platforms for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategic partnerships across the life sciences and government sectors. Investor Relations Contact: Your Name: Nathen Fuentes Title CFO [email protected] Company Website: SOURCE: Renovaro Biosciences press release
Globe and Mail
10-06-2025
- Business
- Globe and Mail
Smart Healthcare Is Taking Over. Here's Where the Money's Headed
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, June 10, 2025 /CNW/ -- Both politicians and leaders in academia are touting the AI revolution empowering the frontline of what's dubbed Smart Healthcare. In a recent write-up in Forbes, Prof. Nicos Savva of the London Business School cited recent speeches from former British Prime Minister Tony Blair, who insists that the UK needs to embrace a future with AI doctors and nurses, or risk being left behind. A new report from Wolters Kluwer has experts calling for more clarity around its use, adoption, and business strategy, because most healthcare organizations aren't currently ready to use GenAI tools. But as implementations increase across the sector, so too are major developments coming from innovators, including Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Alphabet, Inc. (NASDAQ: GOOG) (NASDAQ: GOOGL), Omada Health, Inc. (NASDAQ: OMDA), and Inc. (NASDAQ: AMZN).
Globe and Mail
03-06-2025
- Business
- Globe and Mail
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled 'Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions' (Application No. 18/058,752). This patent strengthens Renovaro's AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse biomedical data sources—such as genomics, electronic health records, imaging, and clinical trial data—into a standardized framework for predictive modeling. 'This patent is a strategic milestone for Renovaro,' said David Weinstein, CEO of Renovaro. 'Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights.' Key Drivers for Renovaro: Expands Foundational IP: Builds on core patent (US 11,379,757), granted in July 2022, which protects machine learning pipeline optimization through advanced feature selection and model tuning. Addresses Real-World Challenges: Tackles integration of siloed and heterogeneous data—an unmet need in pharmaceutical R&D and clinical practice. Enhances Commercial Potential: Enables scalable, distributed computing for biomedical analytics across use cases in rare disease, clinical trials, and personalized medicine. Supports Revenue Growth Strategy: Protects Renovaro's differentiated technology approach, critical for commercial partnerships, licensing opportunities, and platform deployment in life sciences and healthcare. The new patent introduces methods that operate across distributed and parallel computing environments, allowing for real-time, reproducible predictive analytics at scale. This infrastructure is vital as the biopharma industry increases reliance on AI to improve efficiency, reduce costs, and accelerate time-to-market for new therapies. This patent allowance reinforces Renovaro's commitment to building category-defining technology platforms that drive value for patients, partners, and shareholders alike. About Renovaro Inc. Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit Forward-Looking Statements This release contains forward-looking statements, including those relating to the pending litigation and the proposed merger. These statements involve risks and uncertainties and are subject to change based on future developments. Renovaro undertakes no obligation to update any forward-looking statements except as required by law. Investor Relations Chris Tyson Executive Vice President MZ Group - MZ North America 949-491-8235 RENB@ For media inquiries, please contact:
Yahoo
03-06-2025
- Business
- Yahoo
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled 'Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions' (Application No. 18/058,752). This patent strengthens Renovaro's AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse biomedical data sources—such as genomics, electronic health records, imaging, and clinical trial data—into a standardized framework for predictive modeling. 'This patent is a strategic milestone for Renovaro,' said David Weinstein, CEO of Renovaro. 'Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights.' Key Drivers for Renovaro: Expands Foundational IP: Builds on core patent (US 11,379,757), granted in July 2022, which protects machine learning pipeline optimization through advanced feature selection and model tuning. Addresses Real-World Challenges: Tackles integration of siloed and heterogeneous data—an unmet need in pharmaceutical R&D and clinical practice. Enhances Commercial Potential: Enables scalable, distributed computing for biomedical analytics across use cases in rare disease, clinical trials, and personalized medicine. Supports Revenue Growth Strategy: Protects Renovaro's differentiated technology approach, critical for commercial partnerships, licensing opportunities, and platform deployment in life sciences and healthcare. The new patent introduces methods that operate across distributed and parallel computing environments, allowing for real-time, reproducible predictive analytics at scale. This infrastructure is vital as the biopharma industry increases reliance on AI to improve efficiency, reduce costs, and accelerate time-to-market for new therapies. This patent allowance reinforces Renovaro's commitment to building category-defining technology platforms that drive value for patients, partners, and shareholders alike. About Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit Forward-Looking StatementsThis release contains forward-looking statements, including those relating to the pending litigation and the proposed merger. These statements involve risks and uncertainties and are subject to change based on future developments. Renovaro undertakes no obligation to update any forward-looking statements except as required by law. Investor Relations Chris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@ For media inquiries, please contact: karen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
23-05-2025
- Business
- Globe and Mail
AI Could Add $461 Billion to Global Healthcare--And These New Platforms Are Leading the Charge
Equity Insider Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 23, 2025 /CNW/ -- Equity Insider News Commentary – A new report from Philips reveals a growing divide between doctors and patients when it comes to AI in healthcare. While 63% of surveyed healthcare professionals believe AI can help improve outcomes, only 48% of patients share that optimism. As researchers explore what's needed for successful AI adoption in healthcare, major players in tech and biotech are already moving ahead—recent updates have come from Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Certara, Inc. (NASDAQ: CERT), CareCloud, Inc. (NASDAQ: CCLD), and Microsoft Corporation (NASDAQ: MSFT).
